Axogen, Inc. (AXGN)Healthcare | Medical Devices | Alachua, United States | NasdaqCM
51.47 USD
-0.26
(-0.503%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 52.49 +1.02 (1.982%) ⇧ (Aug. 28, 2026, 7:35 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:49 a.m. EDT
The immediate picture is a classic 'value trap' with a temporary technical reprieve. Fundamentally, the business is deteriorating; profit margins are negative, return on equity is deeply impaired, and the forward P/E of 73x is pricing in perfection that the current earnings trajectory cannot support. While revenue is growing at 23%, the market is clearly discounting the quality of that growth given the operational losses. The short-term rating sits at 3.5 because the stock is technically rebounding off its lows, trading above its 200-day average, and options flow shows aggressive buying at the $50 strike. This creates a short-term bullish bias as traders defend the psychological round number. However, this is purely a sentiment play; the underlying fundamentals do not justify a higher valuation. Long-term, the investment case remains neutral to bearish. The company lacks a fortress balance sheet, generates negative operating cash flow relative to its scale, and offers no income stream. The recent price recovery is likely a mean reversion from oversold conditions rather than a confirmation of a new growth regime. Investors should view the current rally as a chance to exit or wait for a clearer inflection in profitability before adding to a position. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.059897 |
| AutoARIMA | 0.061466 |
| AutoETS | 0.061467 |
| MSTL | 0.065232 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 1.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.087 |
| Excess Kurtosis | -1.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2010-01-26 |
| Last Dividend Date | 2010-01-26 |
| Debt to Equity Ratio | 7.83 |
| Revenue per Share | 5.071 |
| Market Cap | 2,767,105,024 |
| Forward P/E | 74.19 |
| Beta | 1.14 |
| Profit Margins | -13.36% |
| Website | https://www.axogeninc.com |
As of Aug. 22, 2026, 1:49 a.m. EDT: Speculators are positioning for a near-term bounce with heavy call volume at the $50 strike, suggesting a test of resistance. However, the implied volatility skew is extreme, with put IV nearly doubling call IV, indicating deep fear of a downside gap despite the lack of significant put open interest. The flow suggests a 'long gamma' squeeze scenario where buyers defend the $50 level, but the lack of protective puts implies a high-risk, high-reward speculative setup rather than a hedged trade.
| Date | Dividend | Yield % |
|---|---|---|
| 2010-01-27 | 1.000000 | 22.222222 |
| 2005-02-23 | 0.060000 | 2.608696 |
| 1992-07-10 | 0.041723 | 0.497293 |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.292807 |
| Address1 | 13,631 Progress Boulevard |
| Address2 | Suite 400 |
| All Time High | 56.85 |
| All Time Low | 0.2 |
| Ask | 55.0 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 909,830 |
| Average Daily Volume3 Month | 1,241,956 |
| Average Volume | 1,241,956 |
| Average Volume10Days | 909,830 |
| Beta | 1.143 |
| Bid | 36.78 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 4.776 |
| City | Alachua |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 51.47 |
| Current Ratio | 6.597 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 52.43 |
| Day Low | 50.94 |
| Debt To Equity | 7.83 |
| Display Name | Axogen |
| Dividend Date | 1,265,932,800 |
| Earnings Call Timestamp End | 1,785,326,400 |
| Earnings Call Timestamp Start | 1,785,326,400 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,793,190,600 |
| Earnings Timestamp Start | 1,793,190,600 |
| Ebitda | -5,968,000 |
| Ebitda Margins | -0.023759998 |
| Enterprise To Ebitda | -448.351 |
| Enterprise To Revenue | 10.653 |
| Enterprise Value | 2,675,759,104 |
| Eps Current Year | 0.46429 |
| Eps Forward | 0.69375 |
| Eps Trailing Twelve Months | -0.67 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,264,550,400 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 386 462 6801 |
| Fifty Day Average | 44.5976 |
| Fifty Day Average Change | 6.872402 |
| Fifty Day Average Change Percent | 0.15409803 |
| Fifty Two Week Change Percent | 229.28072 |
| Fifty Two Week High | 52.91 |
| Fifty Two Week High Change | -1.4399986 |
| Fifty Two Week High Change Percent | -0.027216 |
| Fifty Two Week Low | 15.24 |
| Fifty Two Week Low Change | 36.230003 |
| Fifty Two Week Low Change Percent | 2.377297 |
| Fifty Two Week Range | 15.24 - 52.91 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 535,213,800,000 |
| Float Shares | 52,619,618 |
| Forward Eps | 0.69375 |
| Forward P E | 74.19099 |
| Free Cashflow | 18,232,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 622 |
| Fullday Change | -0.259998 |
| Fullday Change Percent | -0.502607 |
| Fullday Price | 52.49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.74556 |
| Gross Profits | 187,264,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02164 |
| Held Percent Institutions | 0.99108005 |
| Implied Shares Outstanding | 53,761,513 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,264,550,400 |
| Last Dividend Value | 1.0 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 773,884,800 |
| Last Split Factor | 105:100 |
| Long Business Summary | Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida. |
| Long Name | Axogen, Inc. |
| Market | us_market |
| Market Cap | 2,767,105,024 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_20946777 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -33,548,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,780,007,837 |
| Number Of Analyst Opinions | 10 |
| Open | 51.55 |
| Operating Cashflow | 15,047,000 |
| Operating Margins | -0.03092 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 99.04 |
| Phone | 386 462 6800 |
| Post Market Change | 1.0200005 |
| Post Market Change Percent | 1.9817377 |
| Post Market Price | 52.49 |
| Post Market Time | 1,787,960,109 |
| Previous Close | 51.73 |
| Price Eps Current Year | 110.857445 |
| Price Hint | 2 |
| Price To Book | 10.776801 |
| Price To Sales Trailing12 Months | 11.0166855 |
| Profit Margins | -0.13356 |
| Quick Ratio | 4.792 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.259998 |
| Regular Market Change Percent | -0.502607 |
| Regular Market Day High | 52.43 |
| Regular Market Day Low | 50.94 |
| Regular Market Day Range | 50.94 - 52.43 |
| Regular Market Open | 51.55 |
| Regular Market Previous Close | 51.73 |
| Regular Market Price | 51.47 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 771,143 |
| Return On Assets | -0.03147 |
| Return On Equity | -0.18205999 |
| Revenue Growth | 0.231 |
| Revenue Per Share | 5.071 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 53,761,513 |
| Shares Percent Shares Out | 0.0626 |
| Shares Short | 3,365,313 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,443,801 |
| Short Name | AxoGen, Inc. |
| Short Percent Of Float | 0.072399996 |
| Short Ratio | 3.16 |
| Source Interval | 15 |
| State | FL |
| Symbol | AXGN |
| Target High Price | 60.0 |
| Target Low Price | 48.0 |
| Target Mean Price | 53.9 |
| Target Median Price | 55.0 |
| Total Cash | 111,412,000 |
| Total Cash Per Share | 2.072 |
| Total Debt | 20,066,000 |
| Total Revenue | 251,174,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 36.7857 |
| Two Hundred Day Average Change | 14.684299 |
| Two Hundred Day Average Change Percent | 0.39918497 |
| Type Disp | Equity |
| Volume | 771,143 |
| Website | https://www.axogeninc.com |
| Zip | 32,615 |